AMPH
Amphastar Pharmaceuticals Inc

1,129
Mkt Cap
$1.12B
Volume
809,392.00
52W High
$49.17
52W Low
$20.39
PE Ratio
9.00
AMPH Fundamentals
Price
$24.03
Prev Close
$24.23
Open
$26.15
50D MA
$26.23
Beta
0.62
Avg. Volume
363,631.35
EPS (Annual)
$3.06
P/B
1.47
Rev/Employee
$360,930.47
Loading...
Loading...
News
all
press releases
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Gap Up Following Strong Earnings
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Gap Up After Better-Than-Expected Earnings...
MarketBeat·9h ago
News Placeholder
More News
News Placeholder
Here's What Key Metrics Tell Us About Amphastar (AMPH) Q3 Earnings
The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks·2d ago
News Placeholder
Amphastar Pharmaceuticals (AMPH) Q3 Earnings and Revenues Top Estimates
Amphastar (AMPH) delivered earnings and revenue surprises of +20.78% and +3.96%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2d ago
News Placeholder
Floyd Petersen Sells 500 Shares of Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) Director Floyd Petersen sold 500 shares of the firm's stock in a transaction dated Monday, November 3rd. The shares were sold at an...
MarketBeat·2d ago
News Placeholder
Amphastar Pharmaceuticals (NASDAQ:AMPH) Director Sells $12,635.00 in Stock
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) Director Floyd Petersen sold 500 shares of the firm's stock in a transaction on Monday, November 3rd. The stock was sold at an average...
MarketBeat·2d ago
News Placeholder
Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates
Personalis (PSNL) delivered earnings and revenue surprises of +14.29% and +5.80%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·9d ago
News Placeholder
Should Investors Buy CorMedix Stock Ahead of Q3 Earnings Report?
CRMD's Q3 momentum, fueled by DefenCath's strong uptake and Melinta's revenue boost, positions the stock for continued growth.
Zacks·11d ago
News Placeholder
How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results?
CorMedix's DefenCath, the first FDA-approved antimicrobial catheter lock, is expected to drive Q3 growth as new Melinta drugs add to momentum.
Zacks·19d ago
News Placeholder
Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks·22d ago

Latest AMPH News

View

Advertisement|Remove ads.

Advertisement|Remove ads.